Project SIRT6 Activator

NCT07500649 | Recruiting

• 1 other identifier: NUS-IRB-2024-806
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 2

Brief Summary

The global ageing population is increasingly affected by age-related diseases, which are challenging healthcare systems. Current treatments often extend lifespan without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process could prevent or delay multiple diseases, enhancing healthspan. Fucoidan, a sulfated polysaccharide from brown macroalgae, is a safe dietary supplement with Sirtuin-6 (SIRT6) activating properties, which are linked to longevity. Clinical studies have shown that it reduces inflammatory markers associated with biological aging and frailty and influences DNA methylation in vitro and in vivo; however, its effects on human DNA methylation remain unknown.

Conditions

Aging

Keywords

Aging; Geroscience; Fucoidan; SIRT6 Activator; DNA methylation; Healthspan; Epigenetic aging clock

Outcome Measures

Primary Outcomes (1)

• Change in blood DNA methylation status, years

  DNA methylation aging clock

  from baseline to end of intervention (6 months)

Secondary Outcomes (33)

• Change in blood inflammatory markers (pg/mL)

  from baseline to end of intervention (6 months)

• Body Mass Index (BMI) change

  from baseline to end of intervention (6 months)

• Waist-to-hip ratio change

  from baseline to end of intervention (6 months)

• Body fat mass (kg) change

  from baseline to end of intervention (6 months)

• Skeletal muscle mass (kg) change

  from baseline to end of intervention (6 months)

Study Arms (2)

SIRT6 activator

EXPERIMENTAL

Participants in this arm will take 2.4 g/day of Fucoidan (or known as SIRT6 activator) supplement for 6 months

Dietary Supplement: Fucoidan

Placebo

PLACEBO COMPARATOR

Participants in this arm will take 2.4 g/day of placebo for 6 months

Dietary Supplement: Placebo

Interventions

Placebo DIETARY_SUPPLEMENT

Eligible participants will be randomized to receive SIRT6 Activator (fucoidan) or Placebo for 6 months.

Placebo

Fucoidan DIETARY_SUPPLEMENT

Eligible participants will be randomized to receive SIRT6 Activator (fucoidan) or Placebo for 6 months.

SIRT6 activator

Eligibility Criteria

• Age: 50 Years - 80 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years males;
• Resident of Singapore (citizenship or permanent residency is not required);
• Prefrail according to Fried frailty phenotype score;
• English-literate who can understand, read and write in English;
• Individuals without severe cognitive impairment, as determined by PI judgment;
• Apparently healthy and non-smokers having not more than 2 of the following conditions. If the conditions are present they have to be stable:
• Hypertension,
• Hyperlipidemia,
• Hyperglycemia,
• Osteopenia/osteoporosis,
• Osteoarthritis,
• COPD,
• Type 2 diabetes.
• Subjects who agree to shave one day before each visit if he has dense facial hairs on their cheeks that could interfere with skin microbiome sampling.

You may not qualify if:

• Pre-existing or history of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke, peripheral vascular disease);
• Current cancer or non-stable chronic obstructive pulmonary disease (COPD);
• Use of anticoagulant medication;
• Consuming seaweed more than 3 times a week;
• Having hairiness, moles, tattoos, scars, irritated skin, etc. on the face which could influence the investigation;
• Having used within the 3 past weeks for more than 3 consecutive days any systemic or topical drugs related to antibiotics or having planned to use these treatments during the study;
• Having a positive serology for HIV, HEPATITIS B, HEPATITIS C\*
• \*Subjects will undergo a serology test, which will be conducted at baseline and at the end of the intervention visit. Only for subjects who accepted to undergo skin microbiopsy sampling;
• Subject with any contra-indication for skin microbiopsies:
• hypersensitivity or any serious reaction to local anesthesia; (lidocaine/prilocaine), local antibiotics, and antiseptics,
• with inherited or acquired hemostasis disorders,
• having had any treatment which may affect the blood coagulation and hemostasis (anti-coagulant medications…),
• having a history of wound healing defects (hypertrophic scars, keloids…).

Sponsors & Collaborators

• National University of Singapore: lead
• University of Rochester: collaborator
• L'Oreal: collaborator
• DoNotAge.org: collaborator

Study Sites (2)

Yong Loo Lin School of Medicine, National University of Singapore

Singapore, Singapore, 117597, Singapore

RECRUITING

NUS Academy for Healthy Longevity, Level 6, MD 11, 10 Medical Dr, Yong Loo Lin School of Medicine, National University of Singapore

Singapore, Singapore

NOT YET RECRUITING

MeSH Terms

Interventions

fucoidan

Central Study Contacts

Andrea Britta Maier, MD PhD

CONTACT

+65 63793186; a.maier@nus.edu.sg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research

Study Record Dates

• First Submitted: February 10, 2026
• First Posted: March 30, 2026
• Study Start: July 1, 2025
• Primary Completion (Estimated): March 31, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: March 30, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

SG (2)